Trial Profile
APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Patisiran (Primary)
- Indications Amyloid polyneuropathy; Familial amyloid neuropathy; Transthyretin-related hereditary amyloidosis
- Focus Registrational; Therapeutic Use
- Acronyms APOLLO
- Sponsors Alnylam Pharmaceuticals
- 24 Jan 2023 Results assessing effect of patisiran on stroke volume in hereditary transthyretin-mediated amyloidosis, published in the European Journal of Heart Failure.
- 29 Aug 2022 Results of pooled analysis assessing quantitative effect of patisiran and vutrisiran on orthostatic hypotension in patients with hATTR amyloidosis with polyneuropathy presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 17 May 2021 Results of post-hoc analysis presented at the 70th Annual Scientific Session of the American College of Cardiology